

Analysis of CD4-positive T cell subpopulation in sarcoidosis

R. GERLI, S. DARWISH*, L. BROCCUCCI, V. MINOTTI*, F. SPINOZZI, C. CERNETTI, A. BERTOTTO† & P. RAMBOTTI *Istituti di Clinica Medica I, *Oncologia Medica e †Clinica Pediatrica, University of Perugia, Perugia, Italy*

(Accepted for publication 14 April 1988)

SUMMARY

Double-labelling immunofluorescence analysis within the CD4⁺ cell subset was carried out in 27 bronchoalveolar lavage fluids and 11 peripheral blood samples of sarcoidosis patients with anti-TQ1, anti-2H4 and anti-4B4 monoclonal antibodies. Helper/inducer CD4⁺TQ1⁻/4B4⁺ cells were strongly increased in the lung and slightly, but significantly, decreased in the blood of sarcoidosis patients with respect to normal controls. No differences were found in the number of both lung and blood CD4⁺2H4⁺ cells between sarcoidosis patients and controls. The findings are further evidence for a compartmentalization of T cell subsets in sarcoidosis.

Keywords sarcoidosis T lymphocytes immune system

INTRODUCTION

Pulmonary sarcoidosis is a systemic disorder of unknown etiology characterized by the presence of granulomas in the lung. Although granulomas are the hallmark of this disease, recent investigations have shown that the first lesion which occurs in the lung is an inflammatory process of the alveolar structures (Crystal, 1981). Studies using bronchoalveolar lavage (BAL), a valuable tool for characterizing the alveolitis of sarcoidosis (Reynolds, 1987), have demonstrated that such an alveolitis mainly consists of T lymphocytes and macrophages (Thomas & Hunninghake, 1987). Despite the increased numbers of both these cell populations, T lymphocytes are increased to a far greater degree. T lymphocytes seem to modulate sarcoidosis activity, since most of lung T cells in patients with active disease belong to the CD4⁺ cell subset (Hunninghake & Crystal, 1981), that mainly exerts a helper activity (Reinherz & Schlossman, 1980). However, a functional heterogeneity within the CD4⁺ cell population has recently been demonstrated. A monoclonal antibody (MoAb), termed 2H4, has been used to subdivide CD4⁺ lymphocyte populations into a helper/inducer subset (CD4⁺2H4⁻) and an inducer of suppression (CD4⁺2H4⁺) for pokeweed mitogen (PWM)-driven and antigen-driven immunoglobulin production (Morimoto *et al.*, 1985a). A monoclonal antibody anti-TQ1 has been utilized to show further that a major inducer of help is the CD4⁺2H4⁻TQ1⁻ lymphocyte subset (Reinherz *et al.*, 1982). More recently, helper/inducer CD4⁺ T cells have been more accurately identified by using anti-4B4 MoAb (Morimoto *et al.*, 1985b). Thus, attempts to define the pulmonary CD4⁺ cells in

sarcoidosis are valuable in characterizing the specific cell subset involved in alveolitis, and useful for understanding the immunological process that may lead to the lung damage.

MATERIALS AND METHODS

Patients and normal volunteers

The study included 27 sarcoidosis patients (nine men, 18 women) with a mean age of 47 years (range, 24–73). Five subjects with idiopathic pulmonary fibrosis (two men, three women; mean age: 46 years, range 30–49) and six normal subjects (three men, three women; mean age: 42 years, range 24–55) acted as the two control groups. Informed consent was obtained from all participants. The diagnosis of sarcoidosis was based on consistent clinical features confirmed by laboratory findings. In all cases, material obtained from lungs, lymph nodes, liver or bone marrow contained non-caseating epithelioid-cell granulomas, with no evidence of inorganic material known to cause granulomatous diseases. Gallium-67 scans were not done.

Preparation of cell suspension

Mononuclear cells were obtained from heparinized peripheral blood (PB) samples and BAL fluid collected after local anaesthesia. A total of 150 ml sterile 0.9% saline was injected in 50 ml aliquots via a fiberoptic bronchoscope. Each aliquot was immediately aspirated and filtered through surgical gauzes and the volume measured. After determination of the total recovered cells, the lavage fluid was centrifuged at 450 g for 10 min at 4°C. The cell pellet was resuspended in Hanks' balanced salt solution (Gibco, Grand Island, NY, USA) without Ca²⁺ and Mg²⁺. Cytocentrifuged slides were prepared and stained with May-Grünwald-Giemsa to determine cell morphology. The mononuclear cells from both PB and BAL were separated by

Correspondence: Prof. P. Rambotti, Istituto di Clinica Medica I, Università di Perugia, Policlinico Montelucente, 06100 Perugia, Italy

Table 1. Sarcoidosis patient characteristics according to the radiological pulmonary picture

Patients*	Age (years)	Race	Sex	Symptom duration (months)	Extrathoracic sarcoidosis	Smoke	Drug therapy	BAL total cells ($\times 10^6$)	BAL total CD4 ⁺ cells ($\times 10^6$)
Stage I <i>n</i> =17	44.2 \pm 11†	caucasians	5M, 12F	12.1 \pm 15	1U, 1AR, 3SS	none	none	20.9 \pm 10	4.3 \pm 5
Stage II <i>n</i> =4	50.7 \pm 16	caucasians	2M, 2F	4.7 \pm 1	1AR	none	none	21.8 \pm 15	4.2 \pm 4
Stage III <i>n</i> =6	52.2 \pm 11	caucasians	2M, 4F	13.8 \pm 9	1AR, 1SS	none	none	22.7 \pm 10	4.7 \pm 3

* I Hilar adenopathy alone II Hilar adenopathy and parenchymal infiltrates III Parenchymal fibrosis alone.

† Mean \pm s.d.

M Male; F Female U Uveitis; AR Arthritis SS Skin sarcoidosis.

Table 2. BAL characteristics of sarcoidosis (SC) patients idiopathic pulmonary fibrosis (IPF) and normal controls (NC) (mean \pm s.d.)

	Vol. recov. (% infused)	Total lymph. ($\times 10^6$)	Lymph. %	CD3+ %	CD4+ %	CD8+ %
SC (27)	51.8 \pm 10	6.1 \pm 5*	25.7 \pm 7	85.0 \pm 8†	66.4 \pm 14	22.1 \pm 11
IPF (5)	50.7 \pm 11	0.6 \pm 0.5	5.0 \pm 3	78.2 \pm 5	56.4 \pm 4	23.9 \pm 4
NC (6)	51.0 \pm 12	1.2 \pm 0.4	10.3 \pm 3	77.6 \pm 4	55.2 \pm 4	24.8 \pm 5

* $P < 0.001$.

† $P < 0.05$.

centrifugation on Ficoll-Hypaque density gradient, washed and resuspended in RPMI-1640 (Gibco) containing 10% fetal calf serum. After depletion of alveolar macrophages by plastic adhesion at 37°C in a 5% CO₂ atmosphere, lymphoid cells (>97%) were adjusted to a concentration of 1×10^6 cells/ml.

Identification of T cell subsets

T lymphocytes and T cell subsets were identified by indirect immunofluorescence technique using 10 μ l of OKT3 (anti-CD3), OKT4 (anti-CD4) and OKT8 (anti-CD8) MoAb (Ortho, Raritan, NJ, USA) (Reinherz & Schlossman, 1980). Ten microlitres of a fluorescein-conjugated goat anti-mouse IgG antiserum (Kallestad, Chaska, MA, USA) was employed as second labelled antibody for each sample. The percentage of fluorescent cells was determined on at least 200 cells with a Leitz Dialux microscope, using phase contrast to evaluate the lymphoid morphology. Two-colour immunofluorescence studies were performed with MoAb TQ1 (Coulter Electronics Ltd, Luton, UK), 2H4 and 4B4 (kindly supplied by Dr. Schlossman, Boston, MA, USA) to dissect the CD4⁺ subpopulation. Appropriate isotype-specific goat anti-mouse IgG antisera conjugated with fluorescein (FITC) or tetramethyl-rhodamine isothiocyanate (RITC) were used as developing reagents for each MoAb (Southern Biotechnology Ass., Birmingham, Al.) (Gerli *et al.*, 1986). Specificity of the isotype-specific goat anti-mouse fluorochrome-conjugated antibodies was proven by the fact that they never cross-reacted with non-corresponding isotype MoAb. Moreover, negative controls for indirect staining with each MoAb were obtained by using mouse MoAb unreactive with human determinants, followed by fluorochrome-labelled goat anti-mouse antibody, or by using the latter reagent alone.

Table 3. PB lymphocyte characteristics of sarcoidosis patients (SC), idiopathic pulmonary fibrosis (IPF) and normal controls (NC) (mean \pm s.d.)

	Lymph./mm ³	CD3+ %	CD4+ %	CD8+ %
SC (11)	1882 \pm 355	77.4 \pm 7.3	50.8 \pm 4.2	28.3 \pm 5.3
IPF (5)	2083 \pm 261	78.5 \pm 5.9	54.6 \pm 4.3	26.4 \pm 3.1
NC (6)	2117 \pm 225	79.7 \pm 5.4	53.8 \pm 4.1	27.3 \pm 2.2

Statistical analysis

The unpaired Student's *t*-test was adopted for sample analysis. Values of *P* below 0.05 were considered significant.

RESULTS

Patients were classified into stages I (17 patients), II (four patients) and III (six patients), according to the radiological pulmonary pattern. Table 1 shows the relationship between radiological findings and clinical and BAL data of the patients. In particular, the three radiologically distinct groups of patients manifest no difference in either total cells or the number of CD4⁺ cells recovered in BAL. As shown in Table 2, there was no significant difference in the percentage of BAL fluid recovered from sarcoidosis patients and controls. Analysis of bronchoalveolar cells revealed that patients had increased numbers of T lymphocytes. In ten patients the CD3⁺ percentage was greater than 28%, which, according to previously proposed criteria (Hunninghake & Crystal, 1981), suggests the presence of high intensity alveolitis. There were no significant differences in the CD4⁺ and CD8⁺ percentages.

Table 4. Absolute percentages of CD4⁺TQ1⁻, CD4⁺2H4⁺ and CD4⁺4B4⁺ cells in BAL and PB of sarcoidosis patients (SC), idiopathic pulmonary fibrosis (IPF) and normal controls (NC) (mean \pm s.d.)

		CD4 ⁺		
		TQ1 ⁻	2H4 ⁺	4B4 ⁺
BAL	SC (27)	43.1 \pm 22.9*	18.2 \pm 6.0	47.6 \pm 16.9*
	IPF (5)	14.0 \pm 2.0	22.1 \pm 1.9	24.2 \pm 1.6
	NC (6)	13.2 \pm 1.9	23.0 \pm 1.5	23.3 \pm 1.9
PB	SC (11)	8.2 \pm 9.6*	23.1 \pm 2.7	21.8 \pm 1.5*
	IPF (5)	15.1 \pm 2.1	21.9 \pm 1.8	17.9 \pm 1.7
	NC (6)	14.2 \pm 2.3	22.0 \pm 1.5	18.2 \pm 1.7

* $P < 0.001$.

Slight lymphopenia was present in peripheral blood of sarcoidosis patients, but relative CD3⁺, CD4⁺ and CD8⁺ percentages were similar in patients and controls (Table 3). Two-colour immunofluorescence studies revealed a marked increase in sarcoid BAL and a less marked, but statistically significant, decrease in sarcoid PB of CD4⁺TQ1⁻ and CD4⁺4B4⁺ percentages (Table 4). Percentages of CD4⁺2H4⁺ cells in patients' BAL and PB were similar to those of the controls. CD4⁺TQ1⁻ cell number was much higher in the ten patients with high intensity alveolitis (mean \pm s.d. $103 \times 10^3 \pm 54$ cells/ml) than in the 17 patients with low intensity alveolitis ($9 \times 10^3 \pm 7$ cells/ml).

DISCUSSION

Although granulomas are the characteristic pathological feature in sarcoidosis, there is evidence that the initial lesion in the lung is an alveolitis (Crystal *et al.*, 1981; Thomas & Hunninghake, 1987). Macrophages and T cells are the prominent cell populations during inflammation of the alveolar structures, but active lung disease is mainly characterized by a marked increase in the number of the functionally heterogeneous CD4⁺ cell subset (Hunninghake & Crystal, 1981). The present results confirmed that sarcoidosis patients have a much higher number of T lymphocytes in their BAL fluid than controls. The finding that the overall CD4⁺ cell percentage showed no significant decrease was not unexpected, since not all patients manifested signs of active disease (Rossi *et al.*, 1986). Not surprisingly, analysis of lung CD4⁺ cells revealed that most co-expressed 4B4 and lacked the TQ1 antigen. The latter antigen distinguishes two subsets of CD4⁺ inducer cells with distinct repertoires. Both CD4⁺TQ1⁺ and CD4⁺TQ1⁻ cells proliferate equally well to soluble antigens and alloantigens, but more importantly, only CD4⁺ cells lacking the TQ1 epitope can provide a good signal to facilitate B cell differentiation in a pokeweed mitogen-driven system (Reinherz *et al.*, 1982). In the same way, CD4⁺4B4⁺ cells seem to represent a subset with good helper activity for B cell immunoglobulin secretion, but with poor inducer function for CD8⁺ suppressor cells. In addition, the CD4⁺4B4⁺ cell subpopulation proliferates relatively poorly to concanavalin A, but well to tetanus toxoid and mumps antigen (Morimoto *et al.*, 1985b). These functional characteristics are consistent with the

observation that T cells from lungs of sarcoidosis patients are actively proliferating and spontaneously secreting factors that stimulate B cells to differentiate into immunoglobulin-secreting cells. Furthermore, these findings may account, at least in part, for the described defective mitogenic response of sarcoid lung T cells to concanavalin A (Hudspeth *et al.*, 1987). Despite the fact that our patients and controls had a similar number of blood CD4⁺ cells, patient CD4⁺TQ1⁻ and CD4⁺4B4⁺ circulating cells were decreased. This suggests that helper/inducer T lymphocytes are preferentially drawn from peripheral blood to disease activity sites in sarcoidosis. This phenomenon was particularly evident in active disease patients, but we were unable to establish whether such a reduction in CD4⁺TQ1⁻/4B4⁺ blood cells was associated with the known anergy of sarcoidosis or not. It is worth noting that the percentages of patients' CD4⁺2H4⁺ cells, a T cell subset with suppressor/inducer activity (Morimoto *et al.*, 1985a), did not differ greatly from that of controls in either lungs or peripheral blood, thereby confirming that T cells with helper/inducer activity are the main lymphoid cell population involved in regulating the immune response in this disorder. Recent data suggested that assessment of BAL lymphocyte count from sarcoidosis patients has scant clinical utility in predicting the evolution of the disease (Buchalter *et al.*, 1986). Other investigators proposed that more specific determination of BAL lymphocyte characteristics such as phase of cell-cycle, membrane markers specific for T cell subsets or activated T lymphocytes, in both lung and extrathoracic sarcoidosis may be better predictors of outcome and response to treatment than total lymphocytes alone (Cordier, Brune & Revillard, 1986; Semenzato *et al.*, 1986; Wallaert *et al.*, 1986). In particular, it has been proposed that analysis of lung CD4⁺ cells would provide the most useful clinical tool for assessing and perhaps monitoring disease activity in sarcoidosis (Keogh *et al.*, 1983; Bauer *et al.*, 1985; Israel-Biet, Venet & Chrétien, 1986; Costabel *et al.*, 1986). The present data, however, point to the preferential expansion of a particular CD4⁺ cell subset at the sites where inflammation develops. Although, at the moment, follow-up is too short to firmly establish the clinical predictive value of these findings, our data seem to lead to the conclusion that more accurate evaluation of the T cell phenotype in BAL fluid is required to establish the usefulness of BAL analysis in sarcoidosis, and to further improve our knowledge of the role played by cellular immunity in sustaining sarcoid alveolitis.

ACKNOWLEDGMENTS

We wish to thank Dr S. F. Schlossman, Harvard University, Boston MA, USA, for his generous gift of 2H4 and 4B4 monoclonal antibodies and Dr Ivano Gemini for his excellent technical assistance.

REFERENCES

- BAUER, W., GORNY, M.K., BAUMANN, H.R. & MORELL, A. (1985) T-lymphocyte subsets and immunoglobulin concentrations in bronchoalveolar lavage of patients with sarcoidosis and high and low intensity alveolitis. *Am. Rev. Resp. Dis.* **132**, 1060.
- BUCHALTER, S., APP, W., JACKSON, L., CHANDLER, D., JACKSON, R. & FULMER, J. (1986) Bronchoalveolar lavage cell analysis in sarcoidosis. A comparison of lymphocyte counts and clinical course. *Ann. NY Acad. Sci.* **465**, 678.
- CORDIER, G., BRUNE, J. & REVILLARD, J.P. (1986) Alveolar lymphocyte activation during sarcoidosis. *Ann. NY Acad. Sci.* **465**, 140.

- COSTABEL, U., BROSS, K.J., GUZMAN, J., NILLES, A., RUHLE, K.H. & MATTHYS, H. (1986) Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis. *Ann. NY Acad. Sci.* **465**, 418.
- CRYSTAL, R.G. (1981) Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. *Ann. Intern. Med.* **94**, 73.
- GERLI, R., BERTOTTO, A., SPINOZZI, F., CERNETTI, C., GRIGNANI, F. & RAMBOTTI, P. (1986) Phenotypic dissection of cord blood immunoregulatory T cell subsets by using a two-color immunofluorescence study. *Clin. Immunol. Immunopathol.* **40**, 429.
- HUDSPITH, B.N., FLINT, K.C., GERAINT-JAMES, D., BROSTOFF, J. & JOHNSON, N. MCI. (1987) Lack of immune deficiency in sarcoidosis: compartmentalisation of the immune response. *Thorax* **42**, 250.
- HUNNINGHAKE, G.W. & CRYSTAL, R.G. (1981) Pulmonary sarcoidosis. A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. *N. Engl. J. Med.* **305**, 429.
- KEOGH, B.A., HUNNINGHAKE, G.W., LINE, B.R. & CRYSTAL, R.G. (1983) The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. *Am. Rev. Resp. Dis.* **128**, 256.
- ISRAEL-BIET, D., VENET, A. & CHRETIEN, J. (1986) Persistent high alveolar lymphocytosis as a predictive criterion of chronic pulmonary sarcoidosis. *Ann. NY Acad. Sci.* **465**, 395.
- MORIMOTO, C., LETVIN, N.L., DISTASO, J.A., ALDRICH, W.R. & SCHLOSSMAN, S.F. (1985a) The isolation and characterization of the human suppressor inducer T cell subset. *J. Immunol.* **134**, 1508.
- MORIMOTO, C., LETVIN, N.L., BOYD, A.W., HAGAN, M., BROWN, H.M., KORNACKI, M.M. & SCHLOSSMAN, S.F. (1985b) The isolation and characterization of the human helper/inducer T cell subset. *J. Immunol.* **134**, 3762.
- REINHERZ, E.L. & SCHLOSSMAN, S.F. (1980) Regulation of the immune response. Inducer and suppressor T-lymphocyte subsets in human beings. *N. Engl. J. Med.* **303**, 370.
- REINHERZ, E.I., MORIMOTO, C., FITZGERALD, K.A., HUSSEY, R.E., DALEY, J.F. & SCHLOSSMAN, S.F. (1982) Heterogeneity of human T4⁺ inducer T cells defined by a monoclonal antibody that delineates two functional subpopulations. *J. Immunol.* **128**, 463.
- REYNOLDS, H.Y. (1987) State of art. Bronchoalveolar lavage. *Am. Rev. Resp. Dis.* **135**, 250.
- ROSSI, G.A., SACCO, O., COSULICH, E., RISSO, A., BALBI, B. & RAVAZZONI, C. (1986) Helper T-lymphocytes in pulmonary sarcoidosis. Functional analysis of a lung T cell subpopulation in patients with active disease. *Am. Rev. Resp. Dis.* **133**, 1086.
- SEMENZATO, G., AGOSTINI, C., ZAMBELLO, R., TRENTIN, L., CHILOSI, M., ANGI, M.R., OSSI, E., CIPRIANI, A. & PIZZOLO, G. (1986) Activated T cells with immunoregulatory functions at different sites of involvement in sarcoidosis. Phenotypic and functional evaluation. *Ann. NY Acad. Sci.* **465**, 56.
- THOMAS, P.D. & HUNNINGHAKE, G.W. (1987) State of art. Current concepts in the pathogenesis of sarcoidosis. *Am. Rev. Resp. Dis.* **135**, 747.
- WALLAERT, B., RAMON, P., FOURNIER, E.C., PRIN, L., TONNEL, A.B. & VOISIN, C. (1986) Activated alveolar macrophage and lymphocyte alveolitis in extrathoracic sarcoidosis without radiological mediastinopulmonary involvement. *Ann. NY Acad. Sci.* **465**, 201.